The FDA-cleared implant is patient specific, unlike traditional off-the-shelf implants, allowing a personalized fit for each patient’s spine, according to a March 27 press release.
Addressing the unique anatomy of each patient allows for fewer complications, better outcomes and lower costs of care.
The technology was brought to Sarasota Memorial by orthopedic surgeon and spinal implant specialist Ashvin Patel, MD.
While Aprevo was originally cleared to treat the lumber area of the spine, the device was granted a second “breakthrough device designation” by the FDA to develop implants for patients with cervical spine disease.
Sarasota Memorial is now a part of the Compass personalized spine surgery study, which will track Aprevo outcomes for two years for eligible patients who wish to enroll in the study.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
